Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
- Van Not, O.J.
- van den Eertwegh, A.J.M.
- Haanen, J.B.
- van Rijn, R.S.
- Aarts, M.J.B.
- van den Berkmortel, F.W.P.J.
- Blank, C.U.
- Boers-Sonderen, M.J.
- van Eijs, M.J.M.
- de Groot, J.W.B.
- Hospers, G.A.P.
- Kapiteijn, E.
- de Meza, M.
- Piersma, D.
- Stevense-den Boer, M.
- van der Veldt, A.A.M.
- Vreugdenhil, G.
- Wouters, M.W.J.M.
- Suijkerbuijk, K.P.M.
- Blokx, W.A.M.
DOIAbstract
Background: Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were mostly excluded from clinical trials but potentially derive less benefit from immune checkpoint inhibitors (ICIs) due to disease-or treatment-related T-or B-cell dysfunction.Methods: All advanced melanoma patients treated with anti-PD-1-based treatment or tar-geted therapy between 2015 and 2021 were included from the prospective nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS) and melanoma-specific sur-vival (MSS) were analysed for patients with HM (HM+) and without HM (HM-). A cox model was used to account for confounders associated with PFS and M...
Add to ORKG
.jpg%3Fwidth%3D300&w=3840&q=75)
